Medivation, Astellas launch Xtandi

Medivation Inc. (NASDAQ:MDVN) and partner Astellas Pharma Inc. (Tokyo:4503) launched Xtandi enzalutamide in the U.S. to treat metastatic castration-resistant prostate cancer (CRPC) in patients previou...